Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

This Is the One Reason to Own Amazon Stock

By Chris Lau, InvestorPlace Contributor

Amazon followed up with February 2022’s Prime membership price hike in the U.S. with an increase in Canada.

SoFi Could Trade Between $6-$8, Creating a New Bottom. Here’s Why.

By Chris Lau, InvestorPlace Contributor

SOFI stock's weak 2022 outlook angered already fed-up investors unwilling to wait longer for the delayed growth catalysts to play out.

Novavax Stock Is Slumping: Why Buy the Dip?

By Chris Lau, InvestorPlace Contributor

Novavax lost nearly one-fifth of its value in the last week and risks further selling pressure, despite offering an mRNA alternative.

Why Google Is the Safest Nasdaq Stock to Buy

By Chris Lau, InvestorPlace Contributor

Google has multiple catalysts, including a stock split in July that will increase Google’s liquidity and affordability.

7 Cloud Computing Stocks to Buy for April 2022

By Chris Lau, InvestorPlace Contributor

Nasdaq’s steep correction in the first quarter of 2022 hurt these fast-growing stocks the most, creating a good entry point.

Load More